Allergies develop through a two-stage immune process: an initial sensitization phase, where the immune system misclassifies a harmless protein as a danger and builds immunoglobulin E (IgE) antibodies against it, followed by an effector phase, where re-exposure triggers those antibodies to unleash inflammatory chemicals like histamine. Symptoms appear only after sensitization is complete, which is why a person can eat a food for years before reacting.

This distinction matters because most people conflate allergy with intolerance, and most explanations skip the immunology that separates them. Understanding how allergies are developed means understanding a specific antibody class, a specific immune cell, and a specific set of checkpoints that fail. Each of those checkpoints has numbers attached, and each has edge cases where the standard story breaks down.

Sensitization: The First Encounter That Builds IgE

The immune system does not randomly decide to attack pollen. Sensitization requires that an allergen cross a barrier, encounter a particular class of immune cell, and receive signals that bias the response toward IgE rather than the default tolerance.

When a protein allergen enters through the skin, airway, or gut, it is taken up by dendritic cells, which patrol those surfaces. These cells digest the protein and present fragments on their surface to naive T cells in lymph nodes. In most encounters, that presentation generates regulatory T cells and a tolerogenic response. In sensitization, it instead generates T helper 2 (Th2) cells. The deciding factors include the dose of allergen, the route of exposure, and whether the allergen carries intrinsic "adjuvant" properties, such as enzymatic activity or a structure that cross-links receptors on immune cells.

Th2 cells then release cytokines, chiefly interleukin-4 and interleukin-13, that instruct B cells to switch their antibody production to IgE. This class-switch is the committing step. Once allergen-specific IgE is made, it binds to high-affinity receptors on mast cells and basophils, which sit in tissue and blood respectively. Those cells are now armed. The person is sensitized but asymptomatic. Nothing measurable happens on re-exposure until the next step.

One detail worth internalizing: sensitization is silent. There is no rash, no sneeze, no swelling at the time IgE is being built. Sensitization can take days to years depending on the allergen system, and it can occur without any remembered reaction. This is why a first apparent reaction is often not a first exposure. Clinically, the relevant measurements are allergen-specific IgE in serum or skin-prick testing; a positive test indicates sensitization, not allergy (the clinical reactivity), a distinction that drives a large share of misdiagnosis.

Cross-Linking and the Effector Phase

On re-exposure, allergen molecules bind to IgE already anchored on mast cells. Because each mast cell carries many IgE molecules, a single allergen must cross-link at least two adjacent IgE antibodies to trigger anything. This requirement for cross-linking is why very low allergen doses can be tolerated: too few allergen molecules means too few bridges. It also explains why allergens must be at least two binding sites, effectively requiring repeat epitopes or multivalent structure.

Cross-linking clusters the IgE receptors and triggers a signaling cascade that causes the mast cell to release preformed mediators within minutes. Histamine is the best known; it drives vasodilation, vascular leak, itching, and smooth-muscle contraction. Tryptase, proteoglycans, and lipid-derived mediators follow. This is the immediate phase, typically beginning within minutes and peaking roughly 15-30 minutes after exposure.

A late phase arrives hours later. Inflammatory cells, including eosinophils, are recruited to the site, producing a second wave of swelling and mucus production. That two-phase structure explains why some reactions seem to resolve and then worsen. It also means antihistamines, which block histamine receptors, do not address the late-phase component.

The plain version: sensitization builds the loaded gun, and re-exposure pulls the trigger. The trigger pulls hardest when allergen lands in tissue where mast cells are dense, which is why routes of exposure matter. Inhaled pollen lands on airway and conjunctival mast cells. Ingested food contacts gut-associated cells, and in severe cases allergen reaches the bloodstream to trigger systemic mast cells, producing anaphylaxis. A skin contact may produce only local hives depending on dose and allergen potency.

Quantified Context: How Common, How Much, How Fast

Allergic disease is among the most prevalent chronic conditions in the United States. National survey data cited by the CDC indicate that roughly a quarter of adults and about one in five children report at least one allergy, with seasonal allergic rhinitis, eczema, and food allergy the leading categories. Asthma, which is frequently allergic in origin, affects about 1 in 13 Americans.

The numbers that matter most clinically are thresholds, not prevalence. Skin-prick testing is read as positive when a wheal exceeds the negative control by about 3 mm, but positivity reflects sensitization only; the test's predictive value for clinical allergy depends heavily on the allergen and the person's history. Serum specific IgE is reported in kilounits per liter (kU/L), with values at or above roughly 0.35 kU/L considered detectable. These are not diagnostic cutoffs by themselves. The classic caution is that test results must be interpreted against exposure history, because a substantial fraction of sensitized people never react on eating or inhaling the allergen.

Onset timing in the effector phase is similarly concrete: IgE-mediated reactions typically begin within minutes, and the great majority start within 30 minutes of exposure for ingested allergens, with skin and respiratory routes also fast. Symptoms that begin more than two hours after ingestion are less typical of pure IgE mechanisms and warrant a different evaluation, such as for non-IgE food reactions or other diagnoses.

Seasonality adds a predictable layer. Tree pollen peaks in spring, grass pollen in late spring and early summer, and weed pollen, notably ragweed, in late summer and fall, with regional variation. Mold spores track humidity and can persist year-round indoors.

Comparison: Allergy, Intolerance, and Sensitization

Category Underlying mechanism Typical timing Diagnostic test meaning Key example Can it cause anaphylaxis
IgE-mediated allergy Allergen-specific IgE on mast cells; cross-linking releases histamine Minutes to ~2 hours Positive specific IgE or skin test indicates sensitization; clinical history required Peanut allergy Yes
Non-IgE allergy T-cell or other immune mechanisms without IgE Hours to days No reliable IgE test; diagnosis often by elimination and provocation Celiac disease (autoimmune, gluten-triggered) No
Sensitization only IgE present, no clinical reactivity None Positive test with no symptoms on exposure Positive pollen skin test in an asymptomatic person No
Intolerance Enzyme deficiency or pharmacologic effect, not immune Variable, often dose-dependent No immune test; trial-based Lactose intolerance No
Irritant reaction Direct tissue irritation, no immune memory Immediate Not immune Spice or chemical contact No
Autoimmune reaction Immune attack on self-tissue Days to chronic Disease-specific autoantibodies Type 1 diabetes No

This table is the correction most thin explainers miss: a positive test is not the same as an allergy, and lactose intolerance is not a mild milk allergy. They are different conditions with different management.

Timeline: From Sensitization to Symptoms

Stage What happens Approximate timing Observable sign
First exposure Allergen crosses barrier, dendritic cells process it Minutes to hours after contact None
T-cell priming and Th2 bias Naive T cells become Th2 cells in lymph nodes Days to weeks None
IgE class-switch B cells produce allergen-specific IgE Days to weeks after priming None
Mast-cell arming IgE binds receptors on mast cells and basophils Ongoing None (sensitized, asymptomatic)
Re-exposure cross-linking Allergen bridges adjacent IgE, mast cells degranulate Minutes Itching, hives, sneezing, wheeze
Late-phase inflammation Eosinophils and other cells recruited 2-8 hours after early phase Persistent swelling, mucus, fatigue

The table's practical takeaway: the silent stages can last years, and the symptom stage lasts minutes. That mismatch is why people are often surprised by a reaction to a food they have eaten many times. In food allergy, the current understanding is that sensitization usually precedes clinical reactivity, though the exact timing is variable and not fully predictable.

Misconceptions and Professional Caveats

The single most common misconception is that repeated small exposures cause allergy. In food allergy specifically, current guidance from major pediatric and allergy societies has reversed older advice: early introduction of allergenic foods, such as peanut, in infancy is recommended for most infants and reduces allergy risk, rather than delaying introduction. Delaying allergenic foods has not prevented allergy and may increase it. This is the counterintuitive finding that separates current guidance from what many parents were told a generation ago.

A second misconception is that allergy is purely genetic and fixed. Genetics contributes substantially; having one allergic parent raises risk, and two allergic parents raise it further, but no single gene determines allergy. Environmental exposures, including early-life microbial exposure, influence whether genetic predisposition becomes disease.

A professional caveat that deserves prominence: sensitization is not disease. Up to a large fraction of sensitized individuals tolerate the allergen clinically. Over-reading test panels produces false diagnoses, unnecessary avoidance, and anxiety. Allergy diagnosis is a history-first discipline, with testing used to confirm a suspicion the history already raised.

Consider also the hygiene-related framing. The observation that allergic disease is more common in urban, higher-income settings than in some rural settings has been used to argue that reduced early microbial exposure biases the immune system toward Th2 responses. The mechanism is plausible but complex, and it has not produced a simple intervention. Avoid oversimplifying it into "too clean causes allergy."

Flag these as red-flag warning signs that require urgent medical evaluation:

Any breathing difficulty, throat tightness, or voice change after exposure. Widespread hives combined with vomiting, dizziness, or a sense of impending doom. Symptoms that begin or worsen after the initial treatment of a reaction, suggesting a late-phase or biphasic course. A first reaction in an adult with no prior allergy history who has new medication or insect exposure. An infant with persistent eczema, poor growth, or blood in the stool, which can signal food-related disease.

Practical Actions and What They Can and Cannot Do

Allergen avoidance remains the foundation for diagnosed IgE-mediated food allergy, but it must be calibrated to a confirmed diagnosis, not to a test panel. Concrete steps:

Get a history-driven diagnosis. A clinician should match symptoms to exposure timing before ordering tests. Do not treat a positive skin test alone as a diagnosis. For suspected food allergy, ask about an elimination trial followed by supervised reintroduction when appropriate. Do not self-eliminate multiple foods indefinitely; prolonged elimination in children risks nutritional deficiency. For seasonal rhinitis, reduce outdoor exposure during peak pollen hours, typically morning and dry windy days, and shower and change clothing after outdoor time. For asthma with allergic triggers, follow a written action plan from a clinician rather than adjusting medications independently. For an infant at higher risk of food allergy, discuss early introduction of peanut-containing foods with a pediatric clinician, ideally beginning around 4-6 months in appropriately developed infants, based on current society guidance. Do not use unproven "allergy elimination" diets or supplements as substitutes for evaluation. This includes IgG food testing, which major allergy societies advise against for allergy diagnosis because IgG reflects exposure, not allergic disease.

What these actions cannot do: they cannot reliably prevent allergy in a child with strong genetic risk, and they cannot convert an established IgE-mediated allergy into tolerance outside of supervised clinical programs such as oral immunotherapy, which carries real risk and is not a do-it-yourself intervention. Current clinical recommendations on immunotherapy are evolving; patients should discuss eligibility with an allergist rather than relying on general sources.

Cost and access are practical barriers worth naming. Allergen-free specialty foods often carry price premiums, and epinephrine autoinjectors have historically had high list prices; multiple sources report list prices in the range of several hundred dollars without insurance, while generics have lowered out-of-pocket costs substantially. Insurance coverage for allergy testing and immunotherapy varies. These figures change, so verify with a pharmacy or insurer rather than trusting any single number.

Limitations: What the Mechanism Story Leaves Out

The IgE-mast-cell model is well supported and explains most immediate allergic reactions, but it is incomplete. Non-IgE food reactions, including some forms of food-protein-induced enterocolitis and eosinophilic gastrointestinal disease, involve different mechanisms and are often diagnosed by elimination and biopsy rather than by IgE testing. Celiac disease is autoimmune, not allergic, and its diagnosis depends on serology and biopsy, not allergen-specific IgE.

The sensitization mechanism also fails to predict clinical course. Many children with milk or egg sensitization outgrow it, while peanut and tree nut allergy more often persist, and the reasons for the difference are not fully resolved. Thresholds for reactivity vary widely between individuals; there is no universal "safe dose" of an allergen. And the environmental contributors to sensitization, such as the microbiome, pollution, and diet, are associated with allergy risk in large studies but not yet actionable at the individual level.

The honest summary of the field: we know the key steps with high confidence, we can measure sensitization, and we can manage reactions. We cannot reliably predict who will become allergic before it happens, and we cannot yet prevent it except through early-introduction strategies that reduce risk in specific populations. Anyone claiming otherwise is outrunning the evidence.